title: Alemtuzumab (Campath-1H)-induced coagulopathy in renal transplantation.
authors.forename: Shahid G
authors.initials: SG
authors.lastname: Farid
authors.forename: Joe
authors.initials: J
authors.lastname: Barwick
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Goldsmith
authors.forename: Niaz
authors.initials: N
authors.lastname: Ahmad
authors.forename: Charles
authors.initials: C
authors.lastname: Newstead
authors.forename: Richard
authors.initials: R
authors.lastname: Baker
mesh_terms: D000328:Adult; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000009:adverse effects*; D001777:Blood Coagulation / Q000187:drug effects; D001803:Blood Transfusion; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced* / Q000628:therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000009:adverse effects / Q000276:immunology*; D019520:Living Donors; D008775:Methylprednisolone / Q000627:therapeutic use; D010314:Partial Thromboplastin Time; D010949:Plasma; D011517:Prothrombin Time; D016559:Tacrolimus / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D007166:Immunosuppressive Agents; D000074323:Alemtuzumab; D016559:Tacrolimus; D008775:Methylprednisolone